Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.
11,921.50-96.9
Stock Analysis, IPO, Mutual Funds, Bonds & More

Alembic Pharma gets USFDA nod for Febuxostat tablets

Shares of Alembic Pharmaceuticals were trading 3.86 per cent higher at Rs 523 apiece.

PTI|
Jul 02, 2019, 10.56 AM IST
0Comments
New Delhi: Drug firm Alembic Pharmaceuticals Tuesday said it has received approval from the US health regulator for Febuxostat tablets, used to lower high levels of uric acid in adults who have gout.

The approved product is therapeutically equivalent to the reference listed drug Uloric tablets of Takeda Pharmaceuticals USA, Inc.

The company has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Febuxostat tablets in the strengths of 40 mg and 80 mg, Alembic Pharmaceuticals said in a filing to BSE.

Quoting IQVIA data, Alembic Pharma said Febuxostat tablets have an estimated market size of USD 578 million for twelve months ending December 2018.

The company currently has a total of 98 ANDA approvals (87 final approvals and 11 tentative approvals) from USFDA, it added.

Alembic had earlier received tentative approval for this ANDA from the US health regulator.

Shares of Alembic Pharmaceuticals were trading 3.86 per cent higher at Rs 523 apiece on the BSE.

Also Read

Alembic Pharma gets USFDA nod for Desonide Ointment

Alembic Pharma Q2 PAT up 25% at Rs 250 crore

Alembic Pharma JV gets USFDA nod for plaque psoriasis treatment drug

Positive on Mphasis, Infosys; Recommend Alembic Pharma

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.

Other useful Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service